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Letter to the Editor
Evaluation of the SCM test
Sir - Between 1974 and 1981, the British Journal of
Cancer published a series of articles on the
Structuredness of Cytoplasmic Matrix (SCM) Test
devised by Dr Boris Cercek and his colleagues
(Cercek et al., 1974). It was claimed that the test
distinguishes between normal healthy controls and
patients with malignant disease. It was also claimed
that the test distinguishes between patients with
non-malignant conditions and patients with cancer.
Furthermore it was stated that the test makes it
possible to identify the specific type of tumour in
each case (Cercek and Cercek, 1975). In view of the
importance of these claims the study was repeated
by us under identical laboratory conditions. In all,
621 blood samples from controls and various
groups of patients were processed in an exhaustive
and meticulous investigation.
Unfortunately we are unable to confirm any of
the above claims. Throughout the study we
incorporated a large number of modifications
suggested by Dr Cercek. These included utilising
different gradients for lymphocyte separation,
altering the substrate, varying the combinations of
polarising lenses, using disposable plastic tubes,
checking the sensitivity of the photomultiplier, and
replacing the double distilled water to eliminate any
possible impurity. In the end we reluctantly
concluded that the test is of no clinical value. The
details of our investigation have been published
elsewhere (Atkinson et al., 1983).
Yours etc.
R.J. Atkinson, W.S. Lowry & P. Strain
Department of Oncology
Whitla Medical Building
The Queen's University of Belfast
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